These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15250314)

  • 1. [Hyporesponsiveness to recombinant human erythropoietin therapy in anemic patients on hemodialysis].
    Maeda H; Hirakata H
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():307-11. PubMed ID: 15250314
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing erythropoietin hyporesponsiveness.
    Kwack C; Balakrishnan VS
    Semin Dial; 2006; 19(2):146-51. PubMed ID: 16551293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic guidelines for renal anemia in Japan].
    Naito M; Akiba T
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():562-5. PubMed ID: 15250369
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
    Qureshi IZ; Abid K; Ambreen F; Qureshi AL
    Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to recombinant human erythropoietin in hemodialysis patients.
    Drüeke TB
    Am J Nephrol; 1990; 10 Suppl 2():34-9. PubMed ID: 2260616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
    Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
    J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
    Kawabata M; Kasuga S; Hara H; Suyama S; Moriyama K; Takabatake T
    Clin Nephrol; 2001 Mar; 55(3):265-6. PubMed ID: 11316253
    [No Abstract]   [Full Text] [Related]  

  • 8. [Factors influencing responsiveness to treatment in children with renal anemia in end stage renal disease].
    Haliţchi CI; Munteanu M; Brumariu O
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):94-9. PubMed ID: 18677909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron supplementation in renal anemia.
    Fishbane S
    Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European best practice guidelines 14-16: inadequate response to epoetin.
    Hörl WH; Jacobs C; Macdougall IC; Valderrábano F; Parrondo I; Thompson K; Carveth BG
    Nephrol Dial Transplant; 2000; 15 Suppl 4():43-50. PubMed ID: 11052148
    [No Abstract]   [Full Text] [Related]  

  • 11. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of calcitriol on renal anemia in patients under chronic hemodialysis].
    Abou-Khalil N; Makó J
    Orv Hetil; 1996 Jul; 137(27):1469-72. PubMed ID: 9173368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
    Chiang CK; Yang SY; Peng YS; Hsu SP; Pai MF; Huang JW; Hung KY; Wu KD
    Am J Nephrol; 2009; 29(5):392-7. PubMed ID: 18974640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
    Ogawa T; Nitta K
    Contrib Nephrol; 2015; 185():76-86. PubMed ID: 26023017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia in renal insufficiency.
    Santoro A
    Rev Clin Exp Hematol; 2002; Suppl 1():12-20. PubMed ID: 12735211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity of hemodialysis and response to erythropoietin.
    Kotanko P
    N Engl J Med; 1996 Jun; 334(25):1670; author reply 1670-1. PubMed ID: 8628371
    [No Abstract]   [Full Text] [Related]  

  • 17. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
    Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
    G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to recombinant human erythropoietin treatment in thalassaemic patients on chronic haemodialysis: a real clinical entity?
    Tarng DC; Huang TP; Chen TW; Fan CY; Chang JG
    Nephrol Dial Transplant; 1996 Sep; 11(9):1893-5. PubMed ID: 8918654
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
    Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H
    Panminerva Med; 2003 Mar; 45(1):59-62. PubMed ID: 12682621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unusual etiology of erythropoietin resistance: hyperthyroidism.
    Kaynar K; Ozkan G; Erem C; Gul S; Yilmaz M; Sonmez B; Ozdemir F; Ulusoy S
    Ren Fail; 2007; 29(6):759-61. PubMed ID: 17763175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.